Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-25
2010-11-09
Davis, Zinna N (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07829715
ABSTRACT:
There is provided a novel method for producing solifenacin or a salt thereof which is useful as a medicine, particularly a therapeutic agent and/or a preventive agent for a urinary organ system disease such as pollakiuria or urinary incontinence. Illustratively, there are provided (1) a method for producing solifenacin in which 2-(1H-Imidazolylcarbony1)-1-phenyltetrahydroisoquinoline is used as the starting material, (2) a method for producing solifenacin succinate in which (1RS)-phenyltetrahydroisoquinoline-carboxylic acid quinuclidinyl ester is used as the starting material, (3) a method for producing solifenacin in which a lower alkyl quinuclidinyl carbonate is used as the starting material and (4) a method for producing solifenacin in which phenyltetrahydroisoquinoline-carboxylic acid secondary lower alkyl or tertiary lower alkyl ester is used as the starting material and allowed to react with an alkali metal lower alkoxide.
REFERENCES:
patent: 6017927 (2000-01-01), Takeuchi
patent: 0801067 (1997-10-01), None
patent: 2002-104968 (2002-04-01), None
patent: 2003-267977 (2003-09-01), None
patent: 96/20194 (1996-07-01), None
patent: 03/006019 (2003-01-01), None
patent: 03/031405 (2003-04-01), None
patent: 2008/062282 (2008-05-01), None
patent: 2009/142522 (2009-11-01), None
Christine E. Heading, Current Opinion in Central & Peripheral Nervous System Investigational Drugs, 2000, pp. 321-325, vol. 2, No. 3 Pharma Press, LTD.
N. Mealy and J. Castaner, Drugs of the Future, Prous Science, 1999, pp. 871-874, vol. 24, No. 8.
Ken Ikeda, Seiji Kobayashi, Mami Suzuki, Keiji Miyata, Makoto Takeuchi, Toshimitsu Yamada, Kazuo Honda, M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland, Naunyn-Schmiedeberg's Arch Pharmacol, 2002, pp. 97-103, vol. 366, No. 2.
Seiji Kobayashi, Ken Ikeda, Mami Suzuki, Toshimitsu Yamada, Keiji Miyata, Effects of YM 905, a Novel Muscarinic M3-Receptor Antagonist, on Experimental Models of Bowel Dysfunction in Vivo, Jpn J. Pharmacol, 2001, pp. 281-288, vol. 86 No. 3.
Supplementary European search report issued on Mar. 29, 2010 in the counterpart European Application No. 05734743.7-2123.
Office Action issued in Canadian Patent Application No. 2,564,757; dated Aug. 11, 2008.
European Office Action issued Jul. 21, 2010 in corresponding European Application No. 05734743.7.
Inakoshi Masatoshi
Ishii Yusuke
Astellas Pharma Inc.
Davis Zinna N
Sughrue & Mion, PLLC
LandOfFree
Method for producing solifenacin or salts thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing solifenacin or salts thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing solifenacin or salts thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214869